Empagliflozin (trade name Jardiance) has been approved since May 2014 for use by certain adults with type 2 diabetes mellitus. The Institute for Quality and Efficiency in Health Care (IQWiG) has sought to determine whether empagliflozin compared with the appropriate comparator therapy, provides additional benefit.

An additional benefit has not been demonstrated; for four out of five questions, the manufacturer did not provide any relevant information.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/empagliflozin-bei-typ-2-diabetes-zusatznutzen-nicht-belegt.6422.html?&et_cid=4&et_lid=%25208 [German]